… of different doses and dose schedules of everolimus and erlotinib for second- and third-line
combination therapy in patients with metastatic NSCLC. Both daily and weekly dosing …

… aimed to evaluate feasibility and efficacy of a first-line combination of targeted therapies for
advanced non-squamous NSCLC: bevacizumab (B) and erlotinib (E), followed by platinum-…

… dosing of erlotinib (ie, dose level 2A; n = 3). All patients were taking erlotinib 150 mg QD in
dose … requiring a dose reduction to 100 mg QD on day 14 due to an erlotinib-related toxicity. …

… The aim of the study was to evaluate the cost-effectiveness of EGFR mutation analysis
and first-line therapy with erlotinib for mutation-positive patients compared with non-individualized …

… dose limiting toxicities were acneiform rash and diarrhoea. Weekly dosing of erlotinib did not
lead to a maximum tolerated dose… studies following multiple daily dosing of erlotinib 150 mg/…

… It has been also reported that pulsatile administration of high-dose … rate of control and
progression-free survival (PFS) of patients in advanced stages of NSCLC by multiplying the dose …

… metastases patients with first line erlotinib treatment compared with … erlotinib and gefitinib
delivered at standard daily dosing is the maximum tolerated dose or optimal biological dose…

… The dose of gemcitabine used in our study was 1,200 mg/m 2 in 120 min and erlotinib
100 mg/d. This dose of gemcitabine corresponds to the immediately dose level below to the …

… (150 mg/day) combined with intravenous bevacizumab (15 mg/kg on day 1 every 3 weeks)
compared with erlotinib alone at the same dose and administration in the first-line treatment …

… to standard-dose or high-dose conformal radiation therapy with … first-line TKIs rather than
chemotherapy. Preclinical studies demonstrated that EGFR TKIs, such as gefitinib and erlotinib, …